Silverarc Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Silverarc Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.91M	Buy	+297,460	New	+$2.58M	0.3%	57
2025 Q1	–	Sell	-39,733	Closed	-$403K	–	74
2024 Q4	$403K	Buy	39,733 +2,502	+7%	+$30.3K	0.09%	58
2024 Q3	$464K	Hold	37,231	–	–	0.1%	64
2024 Q2	$485K	Hold	37,231	–	–	0.11%	65
2024 Q1	$843K	Sell	37,231 -233	-0.6%	-$4.08K	0.23%	62
2023 Q4	$486K	Hold	37,464	–	–	0.14%	63
2023 Q3	$753K	Buy	37,464 +2,865	+8%	+$64.3K	0.23%	65
2023 Q2	$929K	Sell	34,599 -68,163	-66%	-$2.94M	0.29%	59
2023 Q1	$6M	Buy	+102,762	New	+$5.07M	2.48%	14

Other funds holding KPTI

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CCM

Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Silverarc Capital Management's KPTI Position: Q2 2026 in Review

Silverarc Capital Management opened a new position in Karyopharm Therapeutics (KPTI) in Q2 2026: 297,460 shares worth $2.91M. The stake represents 0.3% of the portfolio and ranks #57 among its holdings. This is a return to the name: Silverarc Capital Management previously reported a position in KPTI as recently as Q4 2024.

Silverarc Capital Management first reported a position in KPTI in Q1 2023 and has held it in 9 quarters since. The position peaked at $6M in Q1 2023. 96 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

Silverarc Capital Management held 297,460 shares of Karyopharm Therapeutics worth $2.91M as of Q2 2026.
Karyopharm Therapeutics was a new Silverarc Capital Management position in Q2 2026.
Karyopharm Therapeutics made up 0.3% of Silverarc Capital Management's portfolio in Q2 2026, its #57 holding.
Silverarc Capital Management first reported a position in Karyopharm Therapeutics in Q1 2023 and has held it in 9 quarters since.
Silverarc Capital Management's Karyopharm Therapeutics position peaked at $6M in Q1 2023.
96 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.